TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03521362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyT1DHero
Description: MyT1DHero is an app with two separate interfaces, one for the parent and one for the child, that work together to help them communicate about diabetes management. The child receives system reminders to enter their blood glucose numbers, and parents receive a notification about each blood glucose test their child enters. Parents are also able to use the app to communicate with their child about their plan for care. The app has customizable blood glucose reminders and ranges, videos of support from other adolescents with T1D, snack lists, and other educational information on T1D.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Other T1D Mobile App
Description: A mobile app will be used in this control/comparison group that only has blood sugar testing reminders and logging capabilities. There will be no other components of the app.
Study: NCT03497858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut Water
Description: participants will consume coconut water and complete a simulated basketball game

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - water
Description: participants will consume Placebo - water and complete a simulated basketball game

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sports drink
Description: participants will consume a sports drink and complete a simulated basketball game
Study: NCT04289805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: letrozole is orally administered (5mg/d) from cycle day 2-3 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard-stimulated cohort
Description: Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: Gonadotrophins started from cycle day 2-3 throughout the ovarian stimulation until ovulation triggering.~Random start protocol: Gonadotrophins started at any time of the cycle and throughout the stimulation.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist.
Study: NCT00921674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin
Description: Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
Study: NCT01127113

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of investigational product
Description: The investigational product will be delivered via intravenous infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of investigational product
Description: The investigational product will be delivered via intravenous infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Infusion of investigational product
Description: The investigational product will be delivered via intravenous infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac magnetic resonance imaging
Description: Cardiac MRI will be performed prior to infusion of investigational product and 1, 2, 7 and 30 days after.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac magnetic resonance imaging
Description: Cardiac MRI will be performed prior to infusion of investigational product and 1, 2, 7 and 30 days after.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac magnetic resonance imaging
Description: Cardiac MRI will be performed prior to infusion of investigational product and 1, 2, 7 and 30 days after.
Study: NCT02888964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add-on therapy
Description: Pioglitazone therapy
Study: NCT02757287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSH-CTP + DESOGESTREL
Description: Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH and the day after the bolus ( estradiol, FSH, Progesterone, LH)~- Quality of Life questionnaire the day after the bolus
Study: NCT02043847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Description: Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous transplant
Description: Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue
Study: NCT01530997

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Description: All patients will receive IMRT. Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day, respectively. The PTV-HR will include the gross tumor and the PTV-SR will include the lymph nodes at risk for harboring micro-metastatic disease (i.e. subclinical disease).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin, 30mg/m2, will be given intravenously over 60 minutes weekly during IMRT; 6 total doses for a total of 180 mg/m2. It is preferred that the doses be administered on days 1, 8, 15, 22, and 29, and 36 of IMRT; however, this is not mandatory.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited surgical evaluation
Description: 4 to 14 weeks after completion of CRT, patients will have at least a biopsy of the primary tumor and limited neck surgery to remove those lymph nodes that were involved with cancer prior to CRT.
Study: NCT03791697

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth 2 week postoperative visit
Description: The patient randomized into the telephone follow up group, will be contacted, at the pre-scheduled date and time, by the urogynecology clinic nurse. The nurse will utilize a scripted series of postoperative questions, which are consistent with questions asked during our standard postoperative clinic visits.~Vital signs and physical examination will be deferred for the patients in the telephone follow up group.~Any patient responses that are not consistent with a usual postoperative course will be escalated to an in person visit. However, these patients will remain in the group, to which they were originally randomized, for research analysis purposes. (Intent to treat)
Study: NCT04060251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyMedica e-vive™ System; CY-1000
Description: All the patients in Group 2 will be given the CyMedica Orthopedics e-vive system 3 weeks before the surgery. The patients will begin using the unit after their first pre-intervention measurements are taken.~Patients will be instructed to apply the e-vive NMES Strength therapy twice a day, 5 days a week. The NMES Strength program is 20 minutes in length. Treatment intensity (adjustable from 1 to 100 in NMES programs) is required to be set at the highest tolerable limit for the patients.~Stimulation from the garment will have the following parameters: frequency of 50 Hz; pulse duration of 5 ms; time on: 12.8 seconds; and time off: 10 seconds. The total contraction time in a 20-minute treatment will be 11 minutes. The waveform will be pulsed and asymmetrical.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iGetBetter telemedicine physical therapy
Description: Group 1 patients will only use a Post-Op program from iGetBetter for the first 3 weeks after surgery. After those 3 weeks have elapsed, Group 1 patients will receive outpatient physical therapy in addition to iGetBetter, approximately twice per week for the next 6-8 weeks as all other groups.
Study: NCT03948854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Registered dietitian
Description: Education on low FODMAP diet is provided in person by a registered dietitian who is an expert on the low FODMAP diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: On-line video program
Description: Education on low FODMAP diet is provided by an on-line program via a link sent through email

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Printed handout
Description: Education on low FODMAP diet is provided through printed handout material at the initial visit.
Study: NCT00771147

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients with diagnosis of advanced renal cell cancer and decision taken by the investigator to prescribe Nexavar®.
Study: NCT01103518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol + Cyproterone acetate
Description: Ethinyl Estradiol (0.035mg) + Cyproterone acetate (2mg), coated tablets. Each treatment cycle consists of one tablet, once per day for 21 days followed by a 7-day rest period. A total of 4 treatment cycles will be completed during the study treatment period.
Study: NCT01103518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinyl Estradiol + Cyproterone acetate
Description: Ethinyl Estradiol (0.035mg) + Cyproterone acetate (2mg), coated tablets. Each treatment cycle consists of one tablet, once per day for 21 days followed by a 7-day rest period. A total of 4 treatment cycles will be completed during the study treatment period.
Study: NCT03948854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietitian-led group
Description: Education on low FODMAP diet is provided in a dietitian-led group setting
Study: NCT03306758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Sodium Bicarbonate was given 1g tid for one month
Study: NCT02933060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal saline (1000 mL)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Study: NCT01909713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Facial Cleanser and Moisturizer SPF 30
Description: Cetaphil® DermaControl™ Foam Wash and Moisturizer SPF 30
Study: NCT03066544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Nerve blocks with bupivacaine will be performed at initial visit
Study: NCT02522260

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance and aerobic training
Description: Group 1) includes strength exercise of the large muscle groups (2-3 sets, 8-12 repetitions on an intensity of 80 % of 1-RM) and 3x3 min high intensity aerobic exercise (16-18 on Borg scale) on an exercise bike or treadmill twice a week for 16 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training
Description: Group 2) includes aerobic exercise on an exercise bike or treadmill, 20 min moderate intensity (13-15 on Borg scale), and 3x3 min high intensity (16-18 on Borg scale) twice a week during 16 weeks
Study: NCT02522260

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard supportive care
Description: Standard supportive care
Study: NCT03508570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given i.p.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03614715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Beta-1A
Description: A single dose of Interferon Beta-1A (Stage 1: 30 or 60 µg, stage 2: 30 µg) was administered IM to healthy subjects (cross over treatment)
Study: NCT03508570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given i.p.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given i.p.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study: NCT03614715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Beta-1A
Description: A single dose of Interferon Beta-1A (Stage 1: 30 or 60 µg, stage 2: 30 µg) was administered IM to healthy subjects (cross over treatment)
Study: NCT00098345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (vandetanib)
Description: oral once daily tablet
Study: NCT04649281

Intervention type: DEVICE
Group type: OTHER
Intervention: Accelerometry
Description: Recording of sleep and physical activity by accelerometry during one week.
Study: NCT03015272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory-Motor Mapping Training
Description: AMMT is a novel, intonation-based intervention that is accompanied by simultaneous tapping each spoken syllable on tuned drums, designed to help minimally verbal children between the ages of 5.5 and12.0 years develop and/or improve speech output. AMMT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in the method.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech-Repetition Therapy
Description: SRT is a novel, non-intonation-based intervention designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. SRT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention. SRT serves as a control intervention to AMMT.
Study: NCT00950781

Intervention type: PROCEDURE
Intervention: ACTH
Description: During the ACTH test an IV will be placed in subjects arms, 25mL of blood will be drawn at -30 minutes and 6mL of blood will be drawn at -15 minutes and 0 minutes respectively. Following, 0.25mg of ACTH will be injected intravenous over 60 seconds, and a final 12mL of blood will be drawn 60 minutes later. That is, a total of 50mL of blood will be drawn to test serum blood hormone levels from the subjects during the ACTH (Hormone) Stimulation Test.
Study: NCT00929578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluphenazine
Description: Intralesional injection of Fluphenazine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intralesional injection of placebo
Study: NCT03066544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naratriptan Pill
Description: one pill will be administered twice each day for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: one tablet will be administered twice each day for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: ketorolac will be administered intramuscularly (IM) or intravenously (IV) at initial visit
Study: NCT01218360

Intervention type: DRUG
Intervention: Physician standard-of-care
Description: Participants will be treated according to their physician's routine practice and the respective Summary of Product Characteristics (SmPC).
Study: NCT01196390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study: NCT01063712

Intervention type: DEVICE
Group type: OTHER
Intervention: Nit-Occlud® PDA-R
Description: Transcatheter implantation of a PDA Device (Nitinol) The catheterism was done under sedation, using a protocol established by inserting a catheter through a femoral artery and/or vein directed to the heart and great vessels. Invasive measurements are obtained in the descending aorta and pulmonary artery. Once in ductal position, we inject iodinated contrast medium that allows us to observe via X-ray the ductal morphology; obtaining accurate measurements to choose the appropriate device. The device is then inserted via the catheter, closing the ductus.~The catheterism provides measures of aortic and pulmonary pressure, before, during and after the closure.
Study: NCT00891111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct Payment
Description: $25 gift card given upon completion of Health Risk Assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regret Lottery
Description: Entered into a lottery upon completion of Health Risk Assessment
Study: NCT01507454

Intervention type: DRUG
Intervention: estradiol, 25 mcg
Description: Vaginal tablets for 6-12 weeks according to product labelling
Study: NCT00997438

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipoic Acid
Description: 300 mg Lipoic acid tablets from Vital Nutrients

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipoic Acid
Description: 300 mg Lipoic acid tablets from Vital Nutrients

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipoic Acid
Description: 300 mg Lipoic acid tablets from Vital Nutrients
Study: NCT01236118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2439821
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2439821
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2439821
Description: Administered subcutaneously
Study: NCT03396393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin tablet
Description: DHA tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin tablet
Description: DHA tablet
Study: NCT01123447

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction and internal fixation
Description: Patients will undergo surgery for open reduction of the fracture and internal fixation with an LC-DC plate and screw fixation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed reduction and short-arm cast
Description: Patient will undergo a closed reduction and be placed in a short-arm (below-elbow) cast for 6 weeks.
Study: NCT00143273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lasofoxifene
Description: 0.05 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasofoxifene
Description: 0.25 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasofoxifene
Description: 0.5 mg tablets
Study: NCT00857779

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous immunotherapy
Description: 7 injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous immunotherapy
Description: 7 injections
Study: NCT04125407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor foot orthoses
Description: The interventional group will receive one customized pair of sensorimotor insoles and will be instructed for their using on a daily bases for the period of 3 months. The duration of using the insoles was established as 1 hour at the day after receiving the insoles. After that, the insoles' tolerance will be assessed based on the email correspondence and further adjustments of insole will be consulted with manufacturer if necessary. Recommended progression in time of using the insoles was established as +1 hour per each day (if possible) with no maximal limit. After 3 weeks, control examination will take place for the control of subjective effect of insoles. Consulting will be offered to the participants through the duration of research. Participants will not undergo any other supplementary treatment (physiotherapy, ...) focusing on the flatfoot deformity.
Study: NCT03787004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-6970
Description: Oral dose CNTX-6970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-6970
Description: Oral dose CNTX-6970
Study: NCT03979794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention for Wellness and Engaged Living (Be-WEL)
Description: Behavioral Intervention for Wellness and Engaged Living (Be-WEL) is a 4-session (2 preoperative, 2 postoperative) telephone intervention focused on improving emotional and physical health through relaxation, behavioral activation, increased physical activity, and adherence to medication and wound care.